Cardiac Phospholamban Antibody / PLN / PLB

Overview

Cardiac Phospholamban Antibody / PLN / PLB is an antibody targeting PLN, raised in Rabbit for protein detection and localization studies where these specifications are required.

Key elements and design rationale

• Target: PLN.
• Antibody identity: Polyclonal (rabbit origin); Rabbit IgG.
• Conjugate/label: Unconjugated (affects detection chemistry and multiplex compatibility).
• Format: Antigen affinity purified.
• Species reactivity: Human, Mouse, Rat.
• Listed applications: WB, Direct ELISA (refer to on-page specifications for application-specific guidance).

Biological background

Phospholamban is a 52 amino acid integral membrane protein that regulates the Ca2+ pump in cardiac muscle and skeletal muscle cells. The subsequent activation of the Ca(2+) pump leads to enhanced muscle relaxation rates, thereby contributing to the inotropic response elicited in heart by beta-agonists. Phospholamban is also expressed in slow-twitch skeletal muscle and some smooth muscle cells. It is observed that human ventricle and quadriceps displayed high levels of phospholamban transcripts and proteins, with markedly lower expression observed in smooth muscles, while the right atrium also expressed low levels of phospholamban. The structure of the human phospholamban gene closely resembles that reported for chicken, rabbit, rat, and mouse. Comparison of the human to other mammalian phospholamban genes indicated a marked conservation of sequence for at least 217 bp upstream of the transcription start site.

Research relevance and current trends

• Comparative expression profiling across cell types, tissues, or perturbations (e.g., drug treatment, genetic editing, or differentiation).
• Subcellular localization and trafficking studies, including co-localization with pathway markers in microscopy-based assays.
• Integration of protein-level measurements with transcriptomics or proteomics to relate abundance to regulation and phenotype.

Common research applications

• Western blotting: researchers commonly compare relative signal levels across conditions and use appropriate negative/positive controls for interpretation.
• ELISA: researchers commonly compare relative signal levels across conditions and use appropriate negative/positive controls for interpretation.

Interpretation should account for antibody-dependent factors such as epitope accessibility, isoforms, and sample preparation differences across workflows.

Notes for experimental interpretation

• Isoforms and PTMs: many targets have multiple isoforms and post-translational modifications that can shift apparent signal or localization; interpret bands/signals accordingly.
• Epitope context: binding can depend on protein conformation and sample processing; region information in the title/immunogen can help anticipate what may be detected.
• Species differences: predicted or validated reactivity may vary by ortholog sequence and sample context; confirm in your model system.
• Control concepts: include negative controls (no-primary/isotype), and where possible genetic controls (KO/KD) or independent antibodies to strengthen conclusions.

Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.